In a report released yesterday, Joseph Schwartz from Leerink Partners reiterated a Buy rating on InflaRx, with a price target of $2.00. The company’s shares closed yesterday at $1.51.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Schwartz is a 5-star analyst with an average return of 31.6% and a 53.61% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Insmed, and Ultragenyx Pharmaceutical.
InflaRx has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
IFRX market cap is currently $101.4M and has a P/E ratio of -1.44.
Read More on IFRX:
Disclaimer & DisclosureReport an Issue
- InflaRx Regains Nasdaq Compliance with Share Price Recovery
- InflaRx regains compliance with Nasdaq min bid price requirement
- InflaRx: Buy Rating Based on Promising C5a/C5aR Strategy and Strong Financial Position
- InflaRx assumed with a Buy at H.C. Wainwright
- InflaRx’s Hold Rating Amid Trial Delays and Uncertain Clinical Data
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
